GlassScriptPhysician profile
Michael Scott Robinson
NPI 1437585155
$15,556.73
in general payments reported to CMS, 2019-2025
28 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $459 · 2022: $515 · 2023: $7,133 · 2024: $6,287 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,568 · Food and Beverage: $2,527 · Travel and Lodging: $2,507 · Consulting Fee: $706 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,568.00 |
| Food and Beverage | $2,527.10 |
| Travel and Lodging | $2,506.85 |
| Consulting Fee | $706.00 |
| Education | $274.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $11,805.67 | 2023-2024 | |
| Janssen Biotech, INC. | $956.80 | 2023-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $412.80 | 2021-2025 | |
| Genzyme Corporation | $289.49 | 2022-2025 | |
| Lilly USA, LLC | $277.07 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $255.15 | 2021-2025 | Dupixent |
| Dermavant Sciences, INC. | $181.38 | 2023-2024 | Vtama |
| Leo Pharma INC. | $163.20 | 2022-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $160.35 | 2021-2025 | |
| Amgen INC. | $139.57 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $112.43 | 2023-2024 | |
| Organon LLC | $112.32 | 2021-2025 | Vtama |
| Incyte Corporation | $109.34 | 2022-2024 | Opzelura |
| Alexion Pharmaceuticals, INC. | $100.26 | 2025 | Koselugo |
| Galderma Laboratories, L.P. | $78.00 | 2021-2025 | Nemluvio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $63.54 | 2021 | |
| Genentech USA, INC. | $44.27 | 2024 | Xolair |
| Pfizer INC. | $44.20 | 2021-2025 | |
| Biofrontera INC. | $38.91 | 2025 | Ameluz |
| Ucb, INC. | $38.55 | 2022-2025 | Bimzelx |
| Journey Medical Corporation | $31.98 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $25.33 | 2021 | |
| Merz North America, INC. | $24.91 | 2025 | |
| Boston Scientific Corporation | $21.73 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.29 | 2021 | |
| Arcutis Biotherapeutics, INC. | $18.41 | 2025 | Zoryve |
| Botanix Sb INC | $17.20 | 2025 | Sofdra |
| Redhill Biopharma INC. | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.